Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-08-21
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of metformin and nelfinavir in
combination with bortezomib in treating patients with multiple myeloma that has come back or
does not respond to treatment. Metformin may stop the growth of tumor cells by disrupting the
energy source within multiple myeloma cells. Nelfinavir and bortezomib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving metformin,
nelfinavir, and bortezomib may work better in treating patients with multiple myeloma.